Skip to main content


Biosimilars are generic versions of biologics that have passed their patent expiration date. The global biosimilars market is expected to be driven by patent expiration of well-known biologics. Increase in approval and sales of biosimilars has led to a significant decline in sales of biologics that had a steady or growing demand.